Comparing the use of d4T-based regimen as lead-in for the first 6 months versus AZT-based first line regimen (A collaboration between SEARCH, The Thai Red Cross AIDS Research Centre, Queen Savang Vadhana Memorial Hospital and University of Hawaii)

Dr. Jintanat Ananworanich: Principal Investigator, Dr. Nittaya Phanuphak: Co-Principal Investigator. This is an open-label safety evaluation to compare a 6-month initial treatment period with either GPO-vir (d4T, 3TC, NVP) or GPO-virZ (ZDV, 3TC, NVP) followed by GPO-virZ. This study is in its planning stages and will be conducted at at least 2 sites in Thailand: The Thai Red Cross AIDS Research Centre and Queen Savang Vadhana Memorial Hospital in Chonburi. One-hundred patients will be enrolled and followed for 72 weeks. There are substudies which will evaluate mitochondrial toxicity, neurotoxicity and pharmacokinetics of nucleosides. The study will likely commence in the fourth quarter of 2007.